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Abstract
The cure rate for late stage epithelial ovarian cancer (EOC) has not significantly improved
over several decades. New and more effective targets and treatment modalities are urgently
needed. RNA-seq analyses of a syngeneic EOC cell pair, representing more and less
aggressive tumor cells in vivo were conducted. Bioinformatics analyses of the RNA-seq
data and biological signaling and function studies have identified new targets, such as ZIP4
in EOC. Many up-regulated tumor promoting signaling pathways have been identified which
are mainly grouped into three cellular activities: 1) cell proliferation and apoptosis resis-
tance; 2) cell skeleton and adhesion changes; and 3) carbohydrate metabolic reprograming.
Unexpectedly, lipid metabolism has been the major down-regulated signaling pathway in
the more aggressive EOC cells. In addition, we found that hypoxic responsive genes were
at the center stage of regulation and detected functional changes were related to cancer
stem cell-like activities. Moreover, our genetic, cellular, biochemical, and lipidomic analyses
indicated that cells grown in 2D vs. 3D, or attached vs. suspended had dramatic changes.
The important clinical implications of peritoneal cavity floating tumor cells are supported by
the data proved in this work. Overall, the RNA-seq data provide a landscape of gene expres-
sion alterations during tumor progression.
Introduction
Epithelial ovarian cancer (EOC) represents the most lethal gynecologic malignancy in the
United States. In 2017, approximately 22,000 women were estimated to be diagnosed with
ovarian cancer and more than 14,000 deaths attributed to the disease were projected to occur.
These numbers have not improved over several decades [1–3]. For those women diagnosed
with advanced stage high grade serous ovarian cancer (HGSOC), which accounts for about
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70% of EOC cases, less than 30% of patients currently survive more than five years after diag-
nosis with little improvement in overall survival over the past 40 years [2–4]. This poor out-
come is mainly attributed to the development of recurrent disease that is often resistant to
chemotherapy. Treatment options for recurrent ovarian cancer are currently limited and not
curative, warranting the development of novel therapeutic strategies.
While large-scale integrated genomic analyses have been conducted by the Cancer Genome
Atlas research network and other organizations [5], the driver genes, functional players, and
critical regulators for each step of EOC development remain to be further identified and char-
acterized. It is well known that the tumor microenvironment plays important roles in tumori-
genesis [6, 7] and in vivo passaged tumor cells usually acquire enhanced tumor progression
abilities, such as SKOV3ip1, HEY-A8 or HEY-1B, and PC-3 and LNCaP derived cell lines [8–
11]. Hence, comparing the gene expression alterations in these cell lines is one of the
approaches to reveal functionally linked genes. However, many of these cell lines and their
parental cells are not fully characterized at the gene expression level.
ID8 syngeneic mouse EOC line was obtained through spontaneous transformation of nor-
mal ovarian surface epithelial cells from C57BL6 mice by repetitive passage in vitro [12]. These
tumor-forming cells were not passaged in vivo. To determine the critical processes of EOC
development, we have developed a highly aggressive EOC cell line (ID8-P1 and ID8-P2) from
ID8-P0 (without in vivo passage) through in vivo passage in immunocompetent and syngeneic
C57BL6 mice [13]. The times to tumor formation and mouse morbidity were reduced from
~90 days for ID8-P0 cells to ~30 days in P1 cells [13]. RNA-seq analysis enables a systems-level
understanding of gene expression changes underlying the dramatic tumorigenic changes
detected.
The next generation of hallmarks of cancer proposed by Hanahan and Weinberg in 2011
[14] includes emerging hallmarks like deregulating cellular energetics (metabolism repro-
graming). Along with the emphasis in intracellular signaling networks with several functional
circuits (proliferation, motility, viability, cytostasis, and differentiation) and tumor microenvi-
ronment, our understanding of the cancer orchestra has been depicted and summarized at a
new level. Our RNA-seq and functional analyses have focused on these important hallmarks.
In particular, we have demonstrated that in vivo passaged ID8 in the peritoneal microenviron-
ment promotes resistance to anoikis in ovarian cancer cells by reprogramming SRC/AKT/
ERK signaling [13, 15].
A ’Warburg effect’ with increased glycolysis has been observed in ID8-P1 vs. -P0 cells [13,
15]. Intense interest in the ’Warburg effect’ has been revived by the discovery that hypoxia-
inducible factor 1 (HIF1) reprograms pyruvate oxidation to lactic acid conversion [16]. Most,
if not all, of solid cancers encounter hypoxic conditions. Cancer cells acquire the ability to sur-
vive hypoxic environments and hypoxia itself can activate adaptive cellular responses that con-
tribute to tumor progression [17, 18]. We have shown previously that the human EOC ascites
environment is hypoxic [18].
CSC or tumor-initiating cells (TIC) represent a rare population of undifferentiated onco-
genic cells responsible for tumor initiation and maintenance. These cells are important in both
tumor recurrence and chemoresistance due to their ability to self-renew, modulate/balance the
differentiation of tumor cells, and survive in the presence of conventional treatment [19–22].
Although many CSC markers, including CD133, CD117, CD44, CD24, Hoechst 33342-exflux-
ing side population (SP), and aldehyde dehydrogenase (ALDH) activity are available to purify
TIC [23, 24], our understanding of CSC in EOC is far from complete, partially related to the
highly heterogeneous nature of the disease. Thus, the identification and further characteriza-
tion of CSCs in EOC is critical for the development of new therapeutic strategies for more
effective treatment of EOC.
Gene alterations in aggressive ovarian cancer cells
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RNA-seq data for mRNA expression in two pairs of ID8-P0 and -PW2 (tumor cells isolated
from tumors developed in the peritoneal wall after two in vivo passages) cells cultured in sus-
pension were obtained using an improved protocol developed in Dr. Nephew’s lab [25]. In this
work, bioinformatic analyses were conducted, which allows the large number of data sets gen-
erated in recent years to be integrated. Networks and pathways revealed by bioinformatic anal-
yses guided genetic, cellular, and biochemical analyses to validate and identify new targets for
EOC. In particular, the expression, signaling mechanisms, and/or functions of several impor-
tant targets were verified in human tissues and/or human EOC cells. Many of the identified
genes/proteins in the RNA-seq data have been previously shown to be up-regulated in human
EOC tissues, with potential clinical correlation, suggesting that the findings have therapeutic
implications.
Results
RNA-seq data generation and analyses
RNA-seq data for mRNA expression in two pairs of ID8-P0 and ID8-PW2 [an ID8-P2 cell line
derived from tumor cells isolated from tumors in the peritoneal wall (PW) after two in vivo
passages] cells cultured in suspension condition were generated. The experimental design of
the study is shown in Fig 1A. While we have developed both ID8-P1 and ID8-P2 (in vivo pas-
sage 1 and 2) cells, we found that the second in vivo passage does not further increase aggres-
siveness in vivo and there are no significant differences in in vitro functional analyses,
including anoikis resistance and cell proliferation. In addition, the ID8-P1 cells obtained from
different organs (including ascites) do not show significant functional differences in vitro and
have similar tumorigenic potential and metastatic organ preference as we have shown
Fig 1. Experimental design and differentially expressed genes (DEG) analyses. A. ID8 syngeneic mouse EOC line was obtained through spontaneous transformation
of normal ovarian surface epithelial cells from C57BL6 mice by repetitive passage in vitro. The ID8-luc cell line (expressing both GFP and luciferase) was established as
described previously. The procedures used to establish ID8-P1 and -P2 cell lines and the cells used for RNA-seq are illustrated in the figure. B. Scatter plot of gene
expression for ID8-P0 and ID8-P2 cell lines. The red and green dots represent up- and down-regulated DEGs, respectively. Several genes mentioned in the current work
are marked in the figure.
https://doi.org/10.1371/journal.pone.0197404.g001
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previously [13]. Hence, although the RNA-seq data were generated from the ID8-P2 vs. -P0
cells, most expression and functional assays were conducted and compared between ID8-P1
and -P0 cells in this work.
The duplicate RNA-seq data displayed highly consistent results, evidence by correlational
analyses (S1 Fig). We confirmed the results using RT-qPCR, Western blot analyses, and/or
ELISA assays in ID8 and human EOC cells for more than 40 genes identified. Differential anal-
ysis was performed with a published software edgeR [26]. Differentially expressed gene (DEG)
was determined if its p-value after false discovery rate (FDR) controlling multiple test correc-
tion was less than 0.01 and its fold change (FC) magnitude between ID8-PW2 and -P0 was
greater than 2-fold (Fig 1B). In this study, we finally identified 1902 up-regulated DEGs in
ID8-PW2 and 1466 down-regulated DEGs in ID8PW2 compared to ID8-P0. More than 6,000
genes with detectable expression levels were not significantly changed between the ID8-PW2
and -P0 cells, including those listed as new and revisited housekeeping genes (Chmp2a, Emc7,
Psmb2, Psmb4, Snrpd3, and Vps29) identified based on analysis of next-generation sequenc-
ing (RNA-seq) data [27], indicating that the expression levels are normalized.
RNA-seq identified new potential target genes
The top candidate is Slc39A4 or ZIP4, a zinc (Zn) transporter, which was 183-fold upregulated
as detected by RNA-seq. We have confirmed that ZIP4 is over-expressed in human EOC tissue
and demonstrated its CSC-related activities in human high grade serous ovarian cancer
(HGSOC) cells. Interestingly, the oncolipid lysophosphatic acid (LPA) effectively up-regulates
ZIP4 expression via the nuclear receptor peroxisome proliferator-activated receptor gamma
(PPARγ) [28]. Several putative PPRE elements [29], containing the AGGTCA sequence are
detected in the 10 kb ZIP4 promoter region.
In addition to ZIP4, we found that several other zinc or metal ion regulating proteins were
up-regulated. In fact, the molecular function of GO:0008270~zinc ion binding identified 136
genes upregulated in ID8-PW2 vs. P0 cells (S1 Table). Enpp1, Enpp2 (ATX, the major LPA
producing enzyme), Brca1, Mt1, Mt2, and Pxn are among the list. We have confirmed the
over-expression of Mt1/2, as well as several additional genes (see below).
SOX9 is another gene detected to be up-regulated in ID8-P1 vs. ID8-P0 cells (2.6 fold, P = 1 x
10-26). We have recently determined SOX9’s potential oncogenic activity and regulatory mecha-
nisms controlling SOX9 protein expression in EOC cells (ID8 and HGSOC cells) [30]. SOX9 is
involved in cellular activities related to CSC, including anoikis-resistance, regulation CSC marker
CD44, and spheroid-formation [30]. Interestingly, ZIP4 was an up-stream regulator of SOX9,
since we found that when ZIP4 was knocked out by the CRISPR/Cas9 system in PE04 cells or
ZIP4 overexpression (OE) in PE01 cells as shown previously [28], SOX9 expression was
completely blocked or upregulated by LPA in a ZIP4-dependent manner, respectively (Fig 2).
Identification of major signaling pathways involved in cancer hallmarks
Functional enrichment analyses on DEGs were completed by using an online tool, DAVID
(https://david.ncifcrf.gov,v6.8). A number of gene ontology (GO) functions, KEGG pathways
(KEGG is a collection of databases dealing with genomes, biological pathways, diseases, drugs,
and chemical substances), and other functional annotations were recognized as significantly
over-represented in DEGs up- or down-regulated in ID8-PW2 compared to ID8-P0. These
signaling pathways are involved in several major cancer hallmarks [14], including pathways
controlling cell proliferation; resisting cell death; enabling replicative immortality [such as
GO:0007049~cell cycle, GO:0051301~cell division, mmu04110:Cell cycle, and GO:0006915~a-
poptotic process (anti-apoptosis gene upregulation); Fig 3A]; and activating cell skeleton
Gene alterations in aggressive ovarian cancer cells
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changes, which may result in invasion and metastasis or altered cell-cell and cell matrix
adhesion (such as GO:0005856~cytoskeleton, GO:0042060~wound healing, GO: 0030027
~lamellipodium, and mmu04510:Focal adhesion; Fig 3B). In addition, reprogramming of
carbohydrate metabolism, amino acid, drug, xenobiotics, and redox metabolism was promi-
nently involved (such as mmu00010:Glycolysis/Gluconeogenesis, mmu00480:Glutathione
metabolism, GO:0006096~glycolytic process, GO:0004364~glutathione transferase activity,
GO:0008152~metabolic process; Fig 3C). Unexpectedly, biosynthesis and metabolism of cho-
lesterol, sterol, and lipids were down- regulated pathways (Fig 3D). The genes listed in these
pathways and their FCs are shown in S2 Table.
Cell survival under stress was critical for EOC progression
The bioinformatic data analyses related to cell survival/apoptosis (Fig 3A and S2 Table) are
consistent and supported by our published data [16, 29, 31] and new data presented here. In
our original paper describing ID8-P0 and ID8-P1 cells, we found that enhanced anoikis resis-
tance is a key cellular process associated with greater aggressiveness and tumorigenicity in vivo
[13]. A higher rate of metabolism and autophagy are also associated with increased anoikis
resistance [13].
Genes related to cell-cell adhesion and EMT/MET were differentially
regulated after in vivo passaging
As shown in Fig 3B and S2 Table, many genes involved in cell skeleton, cell-cell, and cell
matrix adhesion were up-regulated. Among the top six genes up-regulated in ID8-P1 cells, two
genes encode important desmosome components, Dsp and Pkp1. Desmoplakin (Dsp,
55.4-fold up; P = 1.2 x 10-196) is an obligate component of functional desmosomes that anchors
intermediate filaments to desmosomal plaques [31]. Plakophilin 1 (Pkp1, 493-fold up; P = 2.1
x 10-167) encodes a member of the arm-repeat (armadillo) and plakophilin (PKP) gene families.
PKPs contain numerous armadillo repeats, localize to cell desmosomes and nuclei, and partici-
pate in linking cadherins to intermediate filaments in the cytoskeleton [32].
We confirmed Dsp and Pkp1 up-regulation in different ID8-P1 cell lines, as well as in the
human EOC SKOV3ip1 vs. SKOV3 cell pairs (Fig 4A and 4B). DSP’s functional involvement
in EOC in anoikis-resistance was shown in shRNA-mediated DSP-knocked down (KD) stable
cell lines (Fig 4C and 4D). We detected two bands for Dsp (Fig 4A). Our KD experiments
using shRNA (Fig 4C) showed that both of the bands were affected, suggesting that they both
belong to Dsp. Whether these two bands represent different post-translational modification(s)
Fig 2. ZIP4 expression regulated SOX9 expression. A. In PE04-ZIP4-knockout cell lines (K36 and K37 [28]), SOX9 expression was blocked. B. In PE01-ZIP4-
overexpression clones, LPA-induced up-regulation of SOX9.
https://doi.org/10.1371/journal.pone.0197404.g002
Gene alterations in aggressive ovarian cancer cells
PLOS ONE | https://doi.org/10.1371/journal.pone.0197404 June 21, 2018 5 / 22
is unknown and requires further investigation. In addition, P1 cells aggregated more and P0
cells tended to be single cells when they were cultured in suspension. Dsp-KD dissociated cell
aggragates/spheroids (Fig 4E), suggesting that desmosomes play an important role in spheroid
formation, which may be directly related to anoikis-resistance and the CSC-like activities.
Compared to other solid adenocarcinomas, which metastasize hematogenously, metastasis
of EOC occurs primarily via peritoneal cavity dissemination, characterized by exfoliation of
cells from the primary tumor, avoidance of detachment-induced cell death (anoikis), move-
ment throughout the peritoneal cavity as individual cells and multi-cellular aggregates, adhe-
sion to and disruption of the mesothelial lining of the peritoneum, and submesothelial matrix
anchoring and proliferation to generate widely disseminated metastases [33]. These steps are
accompanied by phenotypic plasticity, enabling dynamic mesenchymal-to-epithelial (MET)
and epithelial-to-mesenchymal (EMT) transitions [33]. The abnormal expression of several
additional cell-cell adhesion molecules is reflected by their expression changes: Ncam1 (6.2 x,
P = 2.76x10-73); Cdh1) (E-cadherin, 1.6 x, P = 0.02); Cdh2 (N-cadherin, not changed P = 0.79);
Cdh3) (P-cadherin, 3.1 x, P = 8.9 x 10-18); Epcam (4.9 x, P = 1.3 x 10-8), Cdh23 (Otocadherin,
0.41 x, P = 1.9 x 10-6), Vim (Vimentin, 1.4 x, P = 2.0 x 10-7), Tjp1 (ZO-1, 1.2 x, P = 0.004), Zeb1
Fig 3. Altered functions and pathways in ID8-PW2 vs. -P0 cells. GO functions and pathways significantly enriched in altered genes are grouped based on four major
cellular processes. A. Cell proliferation and apoptosis-resistance. B. Cytoskelton/cell adhesion. C. Metabolism (glucose and amino acids). D. Lipid metabolism. Q values
(p-values corrected by FDR multiple test adjustment) for corresponding functions and pathways are shown as red dots.
https://doi.org/10.1371/journal.pone.0197404.g003
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(no change, P = 0.24), Zeb2 (1.3x, P = 0.004), Tgfb1 (1.9 x, P = 3.3x10-10), Tgfb2 (0.41 x,
P = 2.0x10-11) and Ctnnb1 (β-catenin, 1.6 x, P = 5.0 x 10-14). These data indicate that a more
complex and maybe more dynamic EMT/MET occurs in EOC.
Genes related to cell-matrix adhesion and cell skeleton/focal adhesion were
differentially regulated after in vivo passaging
The mmu04510:Focal adhesion and the GO:0005925~focal adhesion pathways identified 37
and 58 genes up-regulated in P1 vs. P0 cells, respectively (Fig 3B and S2 Table). These lists
include several integrin genes, including several integins (Itgb5, Itga11, Itga5), several extra
cellular matrix proteins [Fn1 (fibronectin 1), Col3a1, Col6a3], and other well know cell-cell
and cell-matrix adhesion proteins, as well as cell membrane receptors [such as Tns1, CD44,
Pxn (paxilin), Anxa6 (annexin A6), Adam17, Ctnnb1 (β-catenin), Dab2 (Disabled-2), Pak1
Fig 4. DSP and PKP1 were up-regulated in in vivo passaged EOC cells. A. DSP protein was upregulated in different P1 cell lines vs. P0 cells: PW, Peritoneal wall
metastases-derived P1 cells; OM, omentum metastases-derived P1 cells; Liver, liver metastases-derived P1 cells; Kidney, kidney metastases-derived P1 cells; ME,
mesentery metastases-derived P1 cells; P2, PW-P1 cells in vivo passage one more time; SKOV3ip1, i.p injected SKOV3 cells. B. PKP1 protein was upregulated in
different P1 cell lines vs. P0 cells. C. Knock-down (KD) DSP clones (a and b) in PW-P1 cells by shRNA. The first lane were from PW-P1 transfected with control (ctrl)
shRNA. D. Representative data showing that DSP was involved in anoikis-resistance. Cell survival was analyzed in cell suspension conditions in the presence of 2% FBS.
E. The cell aggregation in P1 cells was inhibited by KD Dsp. Cells were cultured under suspension conditions for 48 hr.
https://doi.org/10.1371/journal.pone.0197404.g004
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(RAC1 Activated Kinase 1), Cttn (cortactin), Fzd1 (frizzled class receptor 1), Palld (Palladin),
Rap1b, Pik3cd, Mapk3, Akt3, and Shc1] (S2 Table).
Differential gene expression and function in suspended and attached EOC
cells
Interestingly, while the expression levels of focal adhesion kinase (Fak, gene name Ptk2, 1.2 x,
P = 0.0084) and paxilin (gene name Pxn, 1.3 x, P = 0.00036), were not strongly up-regulated,
their phosphorylation was enhanced in ID8-P1 vs -P0 cells when cells were cultured in suspen-
sion under FBS starvation condition (Fig 5), suggesting activation of these gene responses to
stresses, such as cell detachment and nutritional deficiency. We further tested several RNA-seq
identified and up-regulated genes in ID8-P1 vs. -P0 cells at the mRNA level using Q-PCR
under detached vs. attached culture conditions. As shown in Fig 6A, the up-regulation of these
genes in ID8-P1 vs. ID8-P0 cells were confirmed and detached cells showed more dramatic
up-regulation. MT1 and MT2 genes were also expressed in several human HGSOC cell lines
and PE04 cells expressed higher levels of these genes than PE01 cells (Fig 6B).
Glycolysis was involved in the increased survivability in ID8-P1 cells
Fig 3C and S2 Table show that the metabolic pathways and genes (glycolysis, amino acid, glu-
tamine and carbohydrate metabolism, and mitochondrion) were up-regulated in ID8-PW2 vs.
-P0 cells. Cells can be rescued from anoikis by enhanced metabolism, which is regulated by
HIF1 and AKT signaling [34]. ID8-P1 cells produce more lactate than ID8-P0 cells in culture
medium [13], suggesting a Warburg effect. Interestingly, robust pH-regulating systems are
needed for bioenergetic processes to combat the excessive generation of lactic and carbonic
acids during glycolysis and metabolic reprogramming [17]. We found that pH pathway is also
an up-regulated pathway in ID8-PW2 cells (S3 Table).
Pyruvate dehydrogenase kinase (PDK1) catalyzes phosphorylation of pyruvate dehydroge-
nase, a key mitochondrial enzyme in the Krebs cycle [16]. Pyruvate kinase muscle (PKM), a rate
limiting glycolytic enzyme, catalyzes the final step of glycolysis and is a critical regulator of glu-
cose consumption [35]. Our RNA-seq data show that Pdk1, Pkm, and Glut1 (Slc2a1) genes were
2.2, 1.3, and 1.7-fold up-regulated, respectively, in ID8-P1 vs. -P0 cells, suggesting that these
genes are transcriptionally regulated and may be functionally involved in anoikis-resistance. We
confirmed that PKM and PDK1 were up-regulated in ID8-P1 vs.–P0 cells (Fig 7A and 7B). The
Fig 5. Focal adhesion kinase (FAK) and paxilin (Pxn) activation was regulated by stresses. Phosphorylation of FAK and PXN was
mainly upregulated when cells were cultured in suspension under starvation. Western blot analysis showing that ID8-P0, ID8-PW1, or
ID8-PE2 cells were cultured in FBS, lipid depleted (charcoal-treated) FBS (Fat-cm), or FBS starved condition in attached or detached
conditions.
https://doi.org/10.1371/journal.pone.0197404.g005
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nature of the multiple bands of Pdk1 detected is unclear and needs to be further investigated.
Shikonin (SHK) and menadione (MD), known PKM2 inhibitors, inhibited anoikis- resistance
in ID8-P1 cells (Fig 7C and 7D). In addition, we found that SHK reduced cell-cell aggregation
and/or spheroid formation in both Murine and human HGSOC cells (Fig 7E).
The hypoxia responsive genes played important roles in more aggressive
EOC cells
GO:0001666~response to hypoxia pathway identified 48 genes significantly up-regulated in
ID8-P1 vs. ID8-P0 cells. The mmu04066:HIF-1 signaling pathway identified 25 genes regulated
Fig 6. Gene regulation confirmed by Q-PCR in mouse and human EOC cell lines. A-B. Mouse ID8 P0/P1 cells (A) or human EOC cells (B) were seeded into 6-well
plates in attached or low-attached plates in suspension, RNAs were extracted with the RNeasy mini kit (Qiagen, Valencia, CA) and reverse transcribed by M-MLV
reverse transcriptase. Quantitative real-time PCR was performed on a Light Cycler 480 (Roche, Indianapolis, IN) with a SYBR Green I Master Mix (Roche, Indianapolis,
IN). mRNA abundance was normalized to GAPDH.
https://doi.org/10.1371/journal.pone.0197404.g006
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by HIF1. These genes are partially overlapping with 67 independent genes identified. We con-
firmed the differential expression of several HIF1α target genes Vegfa, Akt3, Trf, Eno2, Egln3,
Nos2, Pdk1, Pkm, Ucp2, and Glut1 by Q-PCR and/or other biological assays (Fig 8 and Table 1).
We found that ID8-P1 cells produced 3.7-fold more VEGF than P0 cells when cells were
attached (22.7 ng/ml ± 0.1 vs. 6.3 ± 0.2 ng/ml; all results were adjusted to the same cell num-
bers). More interestingly, when cell were cultured in suspension, they produced more VEGF
(141± 5.3 and 36.6 ± 2.4 ng/ml from P1 and P0 cells, respectively), suggesting that compared
to attached tumor cells, detached tumor cells may have enhanced tumor-promoting activities
in at least certain aspects [13, 15].
A subset development/differentiation, and/or stem cell related genes were
upregulated in ID8-P1 or -P2 cells
As shown above, the genes/proteins detected to be up-regulated in ID8-P1 cells exhibited
CSC-like activities. Table 2 lists up-regulated genes involved in development and/or differenti-
ation in ID8-P2/P1 cells vs. -P0 cells. Many of these genes have their roles implicated in CSC-
like properties. In particular, the RNA-seq data showed that at least eight ALDH isoforms
were up-regulated (S2 Table). We determined the total ALDH activity using the AldeFluor
assays (Fig 9). ID8-P1 cells had significant higher ALDH activity than ID8-P0 cells.
Lipid metabolism was down-regulated in ID8-P1 and -P2 cells
Surprisingly, the major down-regulation pathways identified in ID8-PW2 vs. -P0 cells by
RNA-seq were those involved in lipid metabolism, including cholesterol and sterol
Fig 7. PKM and PDK1 were up-regulated in P1 vs. P0 cells and the PKM2 inhibitors inhibited cellular functions. A and B. PKM2 and PDK1 in P0 and different P1
cells (ME, mesentery, PW, peritoneal wall; OM, omentum) as well as human EOC cells (SKOV3 and HEY). C and D. Pretreatment (1 hr) of PKM inhibitors, shikonin
(SHK) and menadione (MD) dose-dependently reduced anoikis- resistance. % of cell survival are shown in the Y-axis. E. ID8-P1 and PE04 formed spheroids was
disrupted by SHK (1.25 μM).
https://doi.org/10.1371/journal.pone.0197404.g007
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biosynthesis (Fig 3D and S2 Table). Several key enzymes involved in cholesterol and fatty acid
synthesis, FDPS, Hmgcr and fatty acid synthase (Fasn) were both down- regulated in ID8-
PW2 vs -P0 cells (0.24 x, P = 6.03 x 10−27; 0.52 x, P = 3.44 x 10-15; and 0.41 x, 6.60 x 10-38,
Fig 8. DEGs up-regulated in ID8-PW2 associated with hypoxia pathway. The gene expression heatmap (four samples) of 67 DEGs associated
with GO:0001666~response to hypoxia and/or mmu04066:HIF-1 signaling pathway.
https://doi.org/10.1371/journal.pone.0197404.g008
Gene alterations in aggressive ovarian cancer cells
PLOS ONE | https://doi.org/10.1371/journal.pone.0197404 June 21, 2018 11 / 22
P = 6.6 x 10−38, respectively). On the other hand, acetyl-CoA carboxylase β (Accb, 3.80x,
P = 1.81x10-15), an enzyme which catalyzes the carboxylation of acetyl-CoA to malonyl-CoA,
the rate-limiting step in fatty acid synthesis and malonyl-CoA-acyl carrier protein transacylase
(Mcat, 2.0 x, P = 1.49x10-5) were up-regulated. It is also interesting to note that Lrp5, a gene
which encodes a transmembrane low-density lipoprotein receptor that binds and internalizes
ligands in the process of receptor-mediated endocytosis, was 6-fold upregulated in ID8-PW2
cells (P = 1.18 x10-116). This protein also acts as a co-receptor with Frizzled protein family
members for transducing signals by Wnt proteins (39). In fact, several Wnt pathway genes
were upregulated (see S2 Table) mmu04390:Hippo signaling pathway, Wnt5b, Wnt10b Fzd6,
Fzd1,Wnt5a, and Wnt4). In addition, the very low-density lipoprotein receptor (Vldlr) was
up-regulated (13.3 x, P = 4.94x10-103).
Table 1. Confirmed hypoxic responsive genes up-regulated in ID8-P1 or–PW2 cells.
Gene name RNAseq FC1 P value Q-PCR
Normalized2
Other assays
Vegfa 7.5 1.38 x 10-68 3.85±1.2 ELISA
Trf 3.5 1.56 x 10-60 8.0±10
Akt3 6.7 3.61 x 10-47 2.35±0.2 pAkt Western [13]
Egln3 3.2 8.96 x 10-44 2.50±1.3
Ucp2 2.4 9.62x10-30 Q-PCR (Fig 6)
Eno2 8.3 3.65 x 10-28 3.25±1.3
Pdk1 2.2 2.64 x 10-21 Western (Fig 4)
Glut1 (Slc2A1) 1.7 3.01 x 10-7 Western [13]
Pkm 1.3 0.011838 Western (Fig 4)
Hif1a 0.84 0.016 (4115) Western (no change; not shown)
1FC: fold change
2Fold change (ID8-P1 vs. P0); normalized to actin expression
https://doi.org/10.1371/journal.pone.0197404.t001
Table 2. Genes related to CSC markers.
Gene Fold P Test
Zip4 183 3.20x10-217 Expression and function [28]
Gas6 18.3 6.43x10-165 Q-PCR (Fig 6)
Piwil2 157 1.55x10-117 Western
Gas7 8.3 2.48x10-100 Q-PCR
Ncam1 6.2 2.76x10-73
Vegfa 7.5 1.38x10-68 ELSA
Kit (Cd117) 43 3.40x10-53 FACS
Akt3 6.7 3.61x10-47 Western [13]
Notch3 11.2 3.03x10-33 Western
Sox9 2.6 1.04x10-26 Western and function [30]
Cd24a 7.7 2.10x10-19
Ctnnb1 (β- catenin) 1.6 5.02x10-14
Epcam 4.9 1.13x10-8
Abcc1 1.5 2.91x10-8
CD44 1.4 8.31x10-6 Western and IF
Lgr5 2.8 0.00091
https://doi.org/10.1371/journal.pone.0197404.t002
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Discussion
An ID8 syngeneic mouse EOC line was obtained through spontaneous transformation of nor-
mal ovarian surface epithelial cells from C57BL6 mice by repetitive passage in vitro [12]. Using
mouse EOC cells has several advantages which would be difficult to achieve using human cells.
1) Human EOC cells from spontaneous transformation without transfection of immortalized
and oncogenes are not presently available. Spontaneous transformation may better represent
the highly heterogeneous human EOC than a genetic altered model. 2) The ID8 cells were
obtained by in vitro passaging and are native to the tumor microenvironment. These cells may
Fig 9. ID8-P1 cells had higher ALDH activity. Aldefluor assays were performed as detailed in Methods. Both ID8-P0 (upper row) and-P1 (lower
row) were stained with ALDEFLUOR kit from StemCell Technologies. ALDH negative (left column) in the presence of the inhibitor DEAB; ALDH
+ positive (right column) in the absence of the inhibitor DEAB.
https://doi.org/10.1371/journal.pone.0197404.g009
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be more sensitive to the microenvironmental regulations. On the other hand, human cancer
cell lines are isolated from human tumors and may be less sensitive to additional in vivo pas-
sages. This notion is supported by our finding that while ID8-P1 dramatically increased tumor
aggressiveness (assessed by tumor/ascites formation time and peritoneal cavity floating tumor
cells survival at early stage post i.p injection), ID8-P2 cells obtained by additional in vivo pas-
sage increased neither the aggressiveness in vivo, nor major survival signaling genes/pathways.
3) Mouse cells, as opposed to human cells, can be used in immune-competent tumor microen-
vironment, which is known to be critical for tumorigenesis [36, 37]. However, even though
ID8 cells produce tumors resembling human high grade serous ovarian cancer (HGSOC) his-
tologically [38], ID8 cells have similar oncogenic signaling pathways as those of human EOC
cells [13, 39, 40], it still has limitations. Walton et al. have conducted whole exome sequencing
of ID8 and found that there are no functional mutations in genes characteristic of human
HGSOC (Trp53, Brca1, Brca2, Nf1, and Rb1), and p53 remained transcriptionally active. ID8
cells also lack other mutations typical of clear cell carcinoma (Arid1a, Pik3ca), low-grade
serous carcinoma (Braf), endometrioid (Ctnnb1), or mucinous (Kras) carcinomas [41]. Genet-
ically manipulated ID8 cells with loss of p53, with or without combination with other genes
(pTen or Nf1) significantly reduced the median survival times of mice i.p. injected with these
cells from ~ 90 days to 40–60 days [41, 42], which are very similar to ID8-P1 cells as we
reported previously [13] and in the current study. As Walton’s ID8 genetic cell lines are superb
for studying the roles of the particular genetic alterations detected in human HGSOC, it is
likely the alterations acquired via in vivo passaging of ID8 cells through their interactions with
the tumor microenvironment, as we reported here, are also related to the pathways regulated
by these genes, reflecting the high heterogeneous, alternative, and flexible regulating mecha-
nisms in cancer cells. Related to pTen, the PI3K-Akt pathway was upregulated in ID8-P1 vs.
-P0 cells with Pik3cd and Akt3 genes upregulated (S2 Table). In contrast, Pik3ip1, a negative
regulator the PI3K pathway [43], was down-regulated in ID8-P1 vs.–P0 cells (0.5.x, P = 2.6 x
10-17). Pten was also down regulated (0.84 x, P = 0.007). Regarding Nf1, a negative regulator of
the Ras/MAPK signaling [44], several Ras-association domain family members, including
Rassf1, 3, and 7 [45], were up-regulated (S2 Table). In addition, several Mapks were upregu-
lated (Mapk3, 4, and 13, S2 Table). Nevertheless, all model systems have their limitations and
each of them may be more suitable to address specific issues. In fact, many results from studies
of mouse-originated tumors have been successfully translated to human discoveries and clini-
cal applications [46] and we have examined many genes revealed by the ID8 RNA-seq analyses
in human EOC cells, supporting the value and relevance to human EOC studies.
The tumor microenvironment is comprised of the stromal cells, the extracellular matrix,
soluble factors, and exosomes [47]. In addition, nutritional, regulatory, and energy factors,
such as ATP, pH, and gas factors (e.g. O2, and NO) also play important roles. In addition to
hypoxia, we found all three Nos genes (Nos1 to Nos3) were up-regulated (S2 Table; Nos3, 5.3x
P = 0.01). Since the original establishment of ID8 cells [12], they have been passaged many
times in vivo. However, the tumorigenic ability of ID8 cells have not been significantly changed
(more than 100 mice have been tested in our labs), with consistent tumor/ascites formation
time ~ 90 days as others reported [12, 38]. On the contrary, only one time in vivo passage has
dramatically changed the gene expression landscape of the cells, as we showed here, supporting
the roles of the tumor microenvironment. The cells and/or factors involved in the regulation
warrant further investigation.
One of the unexpected findings is that the major down-regulated pathways are related to
lipid metabolism, mainly to cholesterol and steroid hormone metabolisms. Lipids, including
cholesterol and fatty acids, have been shown to play tumor-promoting roles in many cancers,
including EOC [48–50]. Statins have been used in the management of several cancers [51, 52]
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Statins target HMG-CoA reductase (Hmgcr), which is the rate-limiting enzyme for cholesterol
synthesis. However, data exist showing that statins may have negative impacts in cancer treat-
ment. For example, statins actually promote invasive breast disease after long-term use [51].
Interestingly, Braicu et al have reported recently that HGSOC patients exhibit profound alter-
ations in lipid metabolism. In particular, they have shown that ovarian cancer patients exhib-
ited an overall reduction of most lipid classes in their serum as compared to a control group
[53]. In addition, despite the overall reduction, there were also specific lipids showing eleva-
tion, and especially alterations in ceramide and triacylglycerol lipid species were dependent on
their fatty acyl side chain composition. We have conducted lipidomic analyses for phospholip-
ids, lysophospholipids, and triacylglycerols (TAGs) in less (ID8-P0) and highly aggressive
(ID0-P1) EOC cell lines [54]. Our results show that the total lipid content analyses are not sig-
nificantly different in ID8-P0 and -P1 cells [54]. However, when cells were cultured under
detached condition, the total lipid mass was dramatically increased (2–3 fold, normalized to
cell numbers) in both ID8-P0 and -P1 cells. In particular, TAG are dramatically increased
(3.2–8.6 fold) when cells were cultured in detached conditions, which were the major contrib-
utors to the overall increases of the total lipid contents [54]. The findings reported by Braicu
et al [53] are highly consistent with our previous [54] and current studies, suggesting the ID8
cell model reflects certain pathologic characteristics of human EOC.
In this work, we showed that more prominent changes in gene expression and/or cellular
functions were observed in cells cultured in 3D or detached vs. 2D or attached conditions. In
addition lipids, and TAGs in particular, are greatly increased when cells are detached [54]. For
EOC, these observations are particularly relevant. Floating tumor cells are likely to be present
at the very early stage of dissemination, as well as the very late stage when tumors and metasta-
ses are fully developed. Floating tumor cells tend to aggregate and are likely to be more drug-
resistant; have higher motility and can develop new metastases; may interact with the stromal
environment with different features from those solid tumor cells; and/or be primed for pro-
ducing tumor- promoting factors more efficiently, as we showed for VEGF. Hence, targeting
floating tumor cells, in addition to attached solid tumor cells, may become an important
dimension of EOC therapeutics.
We have conducted more vigorous functional and signaling studies for ZIP4 and SOX9 [28,
30]. For other genes/proteins, more correlative data were collected and presented in the cur-
rent work, which warrant further investigation. We have tested and confirmed up-regulation
of ZIP4 expression in human EOC tissues [28]. Many of the identified genes/proteins in the
RNA-seq data have been previously shown to be up-regulated in human EOC tissues, with
potential clinical correlations. These include, but are not limited to, ALDH1, CD44, Epcam,
VEGF, Notch3, Wnt/ β-catenin, GLUT1, and PDK1 [55–66]. Some of the other altered gene
expressions are consistent with databases, such as Oncomine, which need to be further veri-
fied. This work is aiming for providing a landscape of how mouse EOC cells progress in vivo,
which are likely to be extended to human EOC as we have shown in several our previous publi-
cations [13, 28, 30] and in the current work.
Materials and methods
Reagents, cell lines and culture
Oleoyl-LPA was from Avanti Polar Lipids (Birmingham, AL). Shikonin (SHK) and menadione
(MD) were from Sigma (St. Louis, MO). Antibodies against p-FAK (Tyr397) and p-PXN
(Tyr118) were from Cell Signaling (Boston, MA, USA). Antibodies against PKM2 and PDH1
were from Abcam. Anti-SOX9 antibody (Cat. Log # AB5535) was from EMD Millipore (Biller-
ica, MA). The pair of PE01/PE04 cell lines were from Dr. Daniela Matei (Northwestern
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University); The ID8 and T29 cell lines were kind gifts from Dr. Paul F Terranova (University
of Kansas Medical Center) and Dr. Jinsong Liu (M.D Anderson), respectively.
The ID8-P0, an ID8-luc cell line expressing both GFP and luciferase was established as
described [39]. Different ID8-P1 and -P2 cell lines were established as previously described
[13]. SKOV3 and SKOV3ip1 were from Dr. Mien-Chie Hung (University of Texas M.D.
Anderson Cancer Center). HEY and HEY-1B cells were form Dr. Gorden Mills (MD Ander-
son). All cell lines were maintained in a humidified atmosphere at 37˚C with 5% CO2. ID8
cells (mouse epithelial ovarian cancer cells) were maintained in high glucose DMEM contain-
ing 5% FBS (ATCC, Manassas, VA) and 100 μg/mL Penicillin/Streptomycin/ Amphotericin B
(PSA). SKOV3 cells were cultured in Dulbecco’s modified Eagle’s medium/F12 supplemented
with 4% FBS. HEY and HEY-1B cells were cultured in RPMI1640 with 5–10% FBS. PE01/
PE04 cells were cultured in RPMI 1640 with glutamine, 10% FBS (ATCC, Manassas, VA), and
100 μg/mL Penicillin/Streptomycin/Amphotericin B (PSA). For serum starvation, cells were
incubated in the basal medium without FBS or antibiotics. LPA treatment was performed in
cells starved from serum for 16–24 hr.
RNA-seq
ID8-P0 and–PW2 cells were cultured in suspension. After 24 hrs, cells were collected for RNA-
seq analyses. A new and improved method for stranded whole transcriptome RNA-seq method
was developed and described in detail previously [25]. Briefly, biological duplicates of cells (107)
were lysed and RNA was extracted according to manufacturer’s protocol (Qiagen RNeasy Mini
kit). Total RNA was fractionated by size using ethanol concentration manipulations. The large
RNA fraction (>200 nt) was fragmented prior to library construction. Ribosomal RNA was
reduced by duplex specific nuclease (DSN) following limited hybridizations of both fractions
and then amplified to add barcodes for multiplexing on the Illumina HiSeq2000 platform.
Bioinformatics analyses
Demultiplexing RNA sequences were performed by CASAVA v1.8.2 and trimming was
accomplished with Trimmomatic v0.22 with additional trimming by fastx_clipper v0.0.13.2.
Read mapping was performed by tophat2 v2.0.6 to the mouse reference genome from
ENSEMBL and bacterial genome with parameters, –b2-very-sensitive—read-edit-dist 2—max-
multihits 100—library-type fr-secondstrand. Mapped reads were then summarized as gene
expression for associated genes using custom perl scripts allowing no more than two mis-
matches. Differential analysis was performed with a published software edgeR [26] to evaluate
the statistical significance of the difference and fold change (FC) between ID8-PW2 and -P0
for each individual gene. The q-values of genes were achieved by FDR adjustment on their p-
values for multiple-test correction. If one gene has q-value less than 0.01 and linear fold change
(FC) larger than 1.2 or less than 0.83, the gene was determined as differentially expressed gene
(DEG). An online tool DAVID (https://david.ncifcrf.gov, v6.8) was used to perform enrich-
ment analysis on DEGs for biological functions and KEGG pathways. A number of gene ontol-
ogy (GO) functions, KEGG pathways, and other functional annotations were recognized as
significantly over-represented (FDR-based multiple-test corrected p-values < 0.05) in either
up- or down-regulated DEGs when comparing ID8-PW2 to ID8-P0.
Stable cell lines
PE04-ZIP4-KO or PE01-ZIP4-OE cell lines were established as described [28]. The Dsp- KD
cell lines were using The Dsp-KD cell lines were established by lentivirus infection of dsp-
shRNA virus. Dsp-shRNA plasmid was from Origene (Cat# TL519230).
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Western blot analysis and quantitative-real time PCR (Q-PCR)
Western blot analyses were conducted using standard procedures and proteins were detected
using primary antibodies and fluorescent secondary antibodies (IRDye 800CW- conjugated or
IRDye 680-conjugated anti-species IgG, Li-Cor Biosciences, Lincoln, NE) as we described pre-
viously [13]. The fluorescent signals were captured on an Odyssey Infrared Imaging System
(Li-Cor Biosciences, Lincoln, NE) with both 700- and 800-nm channels. Boxes were manually
placed around each band of interest, and the software returned near- infrared fluorescent val-
ues of raw intensity with background subtraction (Odyssey 3.0 analytical software, Li-Cor Bio-
sciences, Lincoln, NE). The protein MW marker used was the Pre-stained SDS-PAGE
Standards, broad range (BIO_RAD, Cat. Log # 161–0318).
For quantitative real-time PCR (Q-PCR), mouse ID8 P0/P1 cells were seeded into 6-well
plates in attached or low-attached plates in suspension, RNAs were extracted with the RNeasy
mini kit (Qiagen, Valencia, CA) and reverse transcribed by M-MLV reverse transcriptase. Q-
PCR was performed in a Light Cycler 480 (Roche, Indianapolis, IN) with a SYBR Green I Mas-
ter Mix (Roche, Indianapolis, IN). mRNA abundance was normalized to GAPDH.
ALDH activity assay
The Aldefluor assay (Stem Cell Technologies, Canada) was used to identify cell populations
with ALDH enzymatic activity as described by MacDonagh et al. [67]. The assay was carried
out according to manufacturer’s instructions. Briefly, cells (5 × 105) were suspended in Alde-
fluor assay buffer containing activated Aldefluor reagent, BODIPY- aminoacetaldehyde
(BAAA) for 45 min. The Aldefluor reagent is a fluorescent non-toxic ALDH substrate that freely
diffuses into intact viable cells. In the presence of ALDH, BAAA is converted to BOPIDY-ami-
noacetate (BAA), which is retained within the cells expressing ALDH. A specific ALDH inhibi-
tor, DEAB, was used to inhibit the BAAA-BAA conversion and acts as an internal negative
control for background fluorescence. The brightly fluorescent ALDH1+ve cells were detected
using the green fluorescence channel (520-540nm).
Cell proliferation, anoikis-resistance, colony- and spheroid-formation
assays
Cell proliferation was analyzed based on MTT hydrolysis using Cell Counting Kit-8 (Dojindo
Molecular Technologies, Rockville, MA). Anoikis-resistance and soft agar colony assays were
described in detail previously [13]. For spheroid formation, cells were re- suspended at 1×103
to 1×104 cells/mL in serum-free DMEM/F12 supplemented with 5 μg/mL insulin (Sigma), 20
ng/mL human recombinant epidermal growth factor (EGF; Invitrogen), 10 ng/mL basic fibro-
blast growth factor (bFGF; Invitrogen), and 0.4% bovine serum albumin (BSA; Sigma), fol-
lowed by culturing in 24-or 96-well Ultra Low Attachment plates (Corning, NY). Spheroids
were photographed after seven days in culture.
Statistical analyses
The Student’s t-test was utilized to assess the statistical significance of the difference between
two treatments. The asterisk rating system as well as quoting the P value in this study was  P<
0.05;  P< 0.01; and  P< 0.001. A P value of less than 0.05 was considered significant.
Supporting information
S1 Fig. Reproducibility of RNA-seq data. A. The scatter plot of gene expression between bio-
logical replicates, e.g. two replicates at P0. B. The scatter plot of gene expression between
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different conditions, e.g. one sample at P0 and the other one at PM2. C. Matrix of Pearson cor-
relation coefficients between any two samples showing higher correlations between biological
replicates than those cross different conditions.
(TIF)
S1 Table. DEGs up-regulated in ID8-PW2 vs. -P0 associated with zinc ion binding.
(DOCX)
S2 Table. Gene ontologies (GOs), KEGG pathways and other functions significantly
enriched in DEGs. The associated genes in the pathways with corresponding q-values are
shown. The fold changes (ID8-P2 vs. ID8-P0) are enclosed in the bracket.
(DOCX)
S3 Table. DEGs up-regulated in ID8-PW2 associated with pH pathway. The associated
genes in the pathways with corresponding q-values are shown. The fold changes (ID8-P2 vs.
ID8-P0) are enclosed in the bracket.
(DOCX)
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